glp-1/gip dual agonist weight loss Understand Tirzepatide and Its Effect on Current Therapy GIPR/GLP-1R dual agonist therapies for

Clin Exp Immunol

Moreover, for adults with type 2 diabetes or prediabetes and nonalcoholic fatty liver disease (NAFLD), the ADA suggests considering GLP-1 receptor agonists or dual GIP/GLP-1 receptor agonists as part of the treatment plan

The GLP-1 receptor agonist semaglutide reduces risks of kidney function loss, kidney failure, cardiovascular events, cardiovascular death and all-cause mortality in people with chronic kidney disease and type 2 diabetes

Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-proteincoupled receptor FFAR2

Drugs 32 , 355359 (2023)

74 Exenatide therapy was associated with lower cardiac enzyme values during the first 72 hours and a reduction in infarct size according to cardiac MRI at 1 month compared with placebo